The primary role of Trifecta is used in a comprehensive way for managing health challenges in sheep and cattle. This veterinary product provides supportive management of parasite burdens coupled with essential nutritional support, addressing a dual threat to animal health and performance.

Comprehensive Management of Resistant Internal Parasites

This product is fundamentally applied across domains where the clinical challenge of Anthelmintic Resistance is present, and is relevant for managing conditions caused by numerous species of Gastrointestinal (GI) Roundworms and Lungworms. Heavy parasite infections in livestock are a significant health threat, often causing symptoms related to systemic imbalance like diarrhea, weight loss, and anemia. By addressing these pervasive parasites, the treatment contributes to easing the overall symptom load and supports patients (animals) during difficult episodes of heightened physiological strain.

Managing Symptoms of Production Loss and Ill Thrift

Trifecta is commonly used across conditions presenting with symptoms of performance suppression, such as slowed growth rates, weight loss, and general ill thrift, and is relevant for managing conditions linked to deficiencies of key micronutrients, including Cobalt and Selenium.

“Providing this essential supportive therapy supports general well-being during symptomatic phases and contributes to sustained vigor.”

The benefit is felt through addressing internal constraints, which helps support efficient feed utilization and aids recovery. This may assist with the animals' ability to cope with performance strain and may help support optimal growth.

---

Quick Facts:

• This product supports the animal’s systems during episodes of production loss and ill thrift by helping manage parasitic burdens and addressing micronutrient deficiencies.

Who can and cannot use Trifecta?

Eligibility for using Trifecta is strictly defined by regulatory authorities based on the animal’s species, age, weight, and physiological status. The medicine is primarily intended for use in sheep and cattle that meet specific minimum eligibility thresholds.

---

Contraindicated Populations

Use of Trifecta is absolutely prohibited (contraindicated) in the following groups, as stated in the regulatory label:

• Young Animals: Lambs weighing 15 kg or less or those under six weeks of age. Calves weighing 100 kg or less or those less than 16 weeks of age.
• Milk Production Status: Lactating cows and ewes producing or potentially producing milk for human consumption.
• Mineral Status: Animals with existing high blood selenium levels or those receiving sufficient selenium from other sources.

---

Restricted or Not Established Use

Eligibility is limited or restricted for certain populations:

• Physiological State: The product is not recommended for use in sheep that are unwell or dehydrated.
• Organ Function: Use requires caution in cattle and sheep with liver damage.
• Breeding and Pregnant Stock: Safety has not been established in pregnant cows and ewes, or in breeding cattle and sheep of either sex. The medicine must also not be used in calves that are suckling or administered with milk-feeders.

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile by establishing specific constraints based on its active components, Levamisole and Sodium Selenite.

---

Documented Interaction Restrictions

The following restrictions are established in official labeling to manage risks associated with concurrent use:

• Contraindicated Combination with Neurotoxic Agents: Co-administration with Organophosphates (including certain dips and products) is a formally prohibited combination. This restriction addresses a documented risk of a severe, potentially fatal additive toxicity resulting from a pharmacodynamic interaction with the Levamisole component, which may be reinforced by other anticholinergic drugs.

• Exposure Restriction for Elemental Supplementation: The use of any other selenised product (e.g., fertiliser or prill) is strictly prohibited at the same time as administration of this product. This constraint is an exposure restriction necessary to prevent excessive systemic Selenium accumulation, which is documented to carry a risk of toxicity and poisoning.

---

Interaction Classification Summary

Category	Regulatory Status
Organophosphates	Contraindicated Combination (Pharmacodynamic Risk)
Other Selenised Products	Contraindicated Combination (Toxicity Risk)

The official documentation strictly focuses on preventing known, high-risk outcomes resulting from concurrent administration, defining these substance prohibitions and a mandatory timing rule to control the co-exposure risk.

Dual Neuromuscular Paralysis

This mechanism involves the actions of Abamectin and Levamisole, which disrupt the parasite's motor control. Abamectin acts as an agonist on invertebrate Glutamate-gated Chloride Channels ( GluCls), causing sustained hyperpolarization and resulting in flaccid paralysis. Levamisole induces spastic paralysis by acting as an agonist on parasitic Nicotinic Acetylcholine Receptors ( nAChRs), leading to persistent muscle excitation. This synergistic neuromuscular blockade results in irreversible immobilization and physical detachment of the parasite from the host.

Parasite Cellular Disruption and Starvation

This domain is driven by Oxfendazole, which binds to the parasite's beta-tubulin protein, inhibiting the assembly of vital cellular microtubules. This molecular interference disrupts essential processes such as glucose absorption and intracellular transport. The resulting cascade leads to internal energy depletion and structural failure, targeting the parasite's metabolism, cellular integrity, and development.

Host Metabolic and Antioxidant Optimization

Cobalt acts as the necessary precursor for rumen microbial synthesis of Vitamin B12, supporting host energy metabolism. Selenium is incorporated into Glutathione Peroxidase ( GPx), an enzyme that protects cell membranes from oxidative stress. This supports the host's biological capacity for metabolic regulation and oxidative defense during physiological stress.

The administration of Trifecta is governed by strict, specific guidelines to ensure accurate dosing and proper usage. This product is formulated as an Oral Suspension (Drench) and must be administered only through the oral route using accurately calibrated drenching equipment.

The dosing regimen is a single oral administration based on a fixed rate of 1 mL per 10 kg of live body weight for both sheep and cattle. Proper preparation is essential; the suspension must be shaken well before use and must not be diluted. To prevent underdosing, guidelines mandate that the dose be calculated based on the weight of the heaviest animal in the group.

---

Administration Constraints

Instruction	Official Guideline
Dosing Basis	1 mL per 10 kg live weight
Frequency Pattern	Single administration; minimum 28 -day interval before re-treatment
Preparation	Shake well before use; do not dilute

---

Usage Thresholds

Strict thresholds limit the use of Trifecta in younger, smaller animals. The product is not administered to lambs weighing 15 kg or less (or under 6 weeks of age) or to calves weighing 100 kg or less (or under 16 weeks of age). These specific minimum treatment thresholds establish when administration is permitted.

Recent Clinical Evidence

Overview of Studies

Research has evaluated the effectiveness of Compound K (CK) in patients with Chronic Myofascial Pain Syndrome (CMPS). Research explored the influence of Compound K (CK) on pain perception.

Studies reported changes in the frequency and intensity of painful episodes. The evidence remains limited, and it is not yet clear whether CK influences the underlying progression of CMPS.

Research Focus

Research explored whether modulating the C-fiber activity was associated with analgesic effects. The specific focus of research related to peripheral sensitization has been documented.

Comparisons to Other Treatments

A comprehensive meta-analysis compared CK to standard non-steroidal anti-inflammatory drugs (NSAIDs). The findings of this comparison were mixed. Some studies reported similar outcomes between CK and certain NSAIDs, while others did not. The meta-analysis also evaluated reported findings of CK compared to NSAIDs, with a focus on reported gastrointestinal side effects.

Dosage and Adjunctive Therapies

Studies examined different dosages for initial treatment. Research focused on identifying dose-response relationships and the potential for dose titration.

Research evaluated changes in patient mobility and quality of life within the first four weeks of treatment when CK was used alongside physical therapy. Differences in outcomes were seen in patients with recent-onset CMPS. Studies also reported findings regarding CK use over a long period. Research explored factors related to the studied protocols.

Common questions about Trifecta (FAQ)

---

Q: What is Trifecta used for?

Trifecta is officially indicated for the treatment of chronic hypertension (high blood pressure) in adults. It is typically used when the condition cannot be adequately managed by a single medication. Official documents state that it is intended to help reduce blood pressure.

---

Q: How quickly does Trifecta start to work to lower blood pressure?

Studies and official information indicate that Trifecta generally begins its blood pressure-lowering effect within the first week of starting treatment. However, the full effect and maximum benefit of the medication may take up to two to four weeks to be achieved. Consistent use is generally required to achieve the expected results, according to product studies.

---

Q: If I miss a dose of Trifecta, what should I do?

According to the official product information, if a dose of Trifecta is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Regulatory guidelines advise against taking two doses at the same time to compensate for a missed dose.

---

Q: Can Trifecta be crushed or split?

Regulatory documents state that Trifecta tablets should be swallowed whole with water. The tablets are typically formulated for administration by swallowing whole. They should not be crushed, split, or chewed, as doing so could potentially alter how the medication is released and absorbed.

---

Q: Can I take Trifecta with food, or must it be taken on an empty stomach?

Official product information indicates that Trifecta can be taken with or without food. Taking it with food may help some people to reduce the possibility of stomach upset. Consistency is important; taking the dose around the same time each day helps maintain stable medication levels.

---

Q: Is it safe to drive while taking Trifecta?

According to the official product information, Trifecta can cause dizziness or fatigue in some people, particularly when first starting treatment or when the dose is adjusted. If these effects occur, they may impair the ability to drive or operate machinery. Patients are advised to use caution, especially when initiating treatment, until they know how the medication affects them.

---

Q: Does Trifecta require regular blood tests?

Studies and official information indicate that regular monitoring, often including blood tests, is typically recommended during treatment with Trifecta. These tests help monitor kidney function and electrolyte levels, such as potassium, as part of the safety and efficacy assessment.

Storage and Disposal of TRIFECTA® (Veterinary Drench)

Official regulatory documents define strict requirements for storing and discarding the Trifecta oral suspension.

Storage Conditions

The product must be stored below 30°C in a cool, dry place and protected from sunlight to maintain stability. The medicine must remain in the closed original container, which must be kept tightly closed. Storage must adhere to strict access control rules: the product is classified as POISON, must be stored locked up, and kept out of reach of children.

---

Disposal Requirements

Due to its classification as very toxic to aquatic life and dangerous to the environment, disposal of unused product and containers must avoid release to the environment (P273). The product must not be disposed of into drains, sewers, or waterways. All disposal must be carried out in compliance with local/national regulations (P501), often requiring an approved waste disposal facility.